MCID: VRL003
MIFTS: 43

Variola Major

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Variola Major

MalaCards integrated aliases for Variola Major:

Name: Variola Major 12 15 70
Smallpox 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050508
ICD9CM 34 050.0
SNOMED-CT 67 266193008
UMLS 70 C0037354 C1812609

Summaries for Variola Major

Disease Ontology : 12 A smallpox that results in severe infection, located in skin, has material basis in Variola virus. The infection results in formation of lesions.

MalaCards based summary : Variola Major, also known as smallpox, is related to chickenpox and smallpox, and has symptoms including fever, pruritus and exanthema. An important gene associated with Variola Major is DUSP14 (Dual Specificity Phosphatase 14), and among its related pathways/superpathways are Signal transduction_Erk Interactions- Inhibition of Erk and Primary immunodeficiency. The drugs Sevelamer and Calcium acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and eye.

Wikipedia : 73 Smallpox was an infectious disease caused by one of two virus variants, Variola major and Variola minor.... more...

Related Diseases for Variola Major

Diseases related to Variola Major via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 chickenpox 29.8 CD8A CD4
2 smallpox 11.4
3 variola minor 11.2
4 vaccinia 10.4
5 cork-handlers' disease 10.1 CD8A CD4
6 necrotic uveal melanoma 10.1 CD8A CD4
7 early yaws 10.1 CD8A CD4
8 ventilation pneumonitis 10.1 CD8A CD4
9 diffuse infiltrative lymphocytosis syndrome 10.1 CD8A CD4
10 latent syphilis 10.1 CD8A CD4
11 type 1 diabetes mellitus 23 10.1 CD8A CD4
12 autoimmune lymphoproliferative syndrome, type iia 10.1 CD8A CD4
13 parapsoriasis 10.1 CD8A CD4
14 gastroduodenitis 10.1 CD8A CD4
15 duodenitis 10.1 CD8A CD4
16 primary syphilis 10.1 CD8A CD4
17 norwegian scabies 10.1 CD8A CD4
18 bird fancier's lung 10.1 CD8A CD4
19 skin sarcoidosis 10.1 CD8A CD4
20 metal allergy 10.1 CD8A CD4
21 follicular mucinosis 10.1 CD8A CD4
22 tertiary syphilis 10.1 CD8A CD4
23 spongiotic dermatitis 10.1 CD8A CD4
24 acute retinal necrosis syndrome 10.1 CD8A CD4
25 cerebral lymphoma 10.1 CD8A CD4
26 oral tuberculosis 10.1 CD8A CD4
27 cerebritis 10.1 CD8A CD4
28 invasive malignant thymoma 10.1 CD8A CD4
29 west nile encephalitis 10.1 CD8A CD4
30 granulomatous hepatitis 10.1 CD8A CD4
31 exanthema subitum 10.1 CD8A CD4
32 immunodeficiency 36 10.1 CD8A CD4
33 viral exanthem 10.1 CD8A CD4
34 secondary syphilis 10.1 CD8A CD4
35 glanders 10.1 CD8A CD4
36 oral hairy leukoplakia 10.1 CD8A CD4
37 superficial basal cell carcinoma 10.1 CD8A CD4
38 esophageal candidiasis 10.1 CD8A CD4
39 parotid disease 10.1 CD8A CD4
40 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.1 CD8A CD4
41 ulcerative stomatitis 10.1 CD8A CD4
42 granulomatous dermatitis 10.1 CD8A CD4
43 west nile fever 10.1 CD8A CD4
44 neurosarcoidosis 10.1 CD8A CD4
45 retinitis pigmentosa 46 10.1 CD8A CD4
46 pneumonic tularemia 10.1 CD8A CD4
47 tularemia 10.1 CD8A CD4
48 farmer's lung 10.1 CD8A CD4
49 uveoparotid fever 10.1 CD8A CD4
50 bell's palsy 10.1 CD8A CD4

Graphical network of the top 20 diseases related to Variola Major:



Diseases related to Variola Major

Symptoms & Phenotypes for Variola Major

UMLS symptoms related to Variola Major:


fever; pruritus; exanthema

Drugs & Therapeutics for Variola Major

Drugs for Variola Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4 52757-95-6
2
Calcium acetate Approved, Investigational Phase 4 62-54-4
3 Immunoglobulins Phase 4
4 Immunoglobulins, Intravenous Phase 4
5 Antibodies Phase 4
6 Immunologic Factors Phase 4
7 gamma-Globulins Phase 4
8 Rho(D) Immune Globulin Phase 4
9 Vaccines Phase 4
10 Antiviral Agents Phase 4
11 Chelating Agents Phase 4
12 Calcium, Dietary Phase 4
13
Calcium Nutraceutical Phase 4 7440-70-2 271
14 Iron-Dextran Complex Phase 3
15
Phenol Approved, Experimental Phase 2 108-95-2 996
16
BCG vaccine Approved, Investigational Phase 1, Phase 2
17 Pharmaceutical Solutions Phase 1
18 interferons Phase 1
19 Poly ICLC Phase 1

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 A Post Marketing Study of the Safety, Tolerability, and Pharmacokinetics of TPOXX In Adult Subjects Weighing More Than 120 KG Completed NCT04392739 Phase 4 Tpoxx
2 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
3 A Post-Marketing Open-Label, 5 Period Crossover, Drug-Drug Interaction Study of Orally Adminstered TPOXX When Co-administered With 4 Different Phosphate Binders in Healthy Subjects Not yet recruiting NCT04485039 Phase 4 TPOXX
4 An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects Completed NCT02474589 Phase 3 tecovirimat
5 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
6 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
7 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT03699124 Phase 3
8 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Completed NCT01913353 Phase 3
9 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
10 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
11 Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
12 An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Active, not recruiting NCT02977715 Phase 3
13 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
14 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
15 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
16 A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination Completed NCT00189904 Phase 1, Phase 2
17 Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
18 Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects Completed NCT00189956 Phase 2
19 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
20 The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination Completed NCT00053482 Phase 2
21 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
22 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
23 A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00050505 Phase 2
24 A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00032708 Phase 2
25 Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults. Completed NCT00258947 Phase 2
26 Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
27 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
28 A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
29 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis Completed NCT00316602 Phase 2
30 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. Completed NCT00316589 Phase 2
31 A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects Completed NCT00316524 Phase 2
32 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
33 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
34 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
35 A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE® Using Three Immunization Schedules and Two Modes of Delivery Completed NCT01827371 Phase 2
36 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
37 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
38 Open Label, Dose Escalation and Age De-escalation for ChAdOx1 85A in Ugandan Adults and Adolescents, Followed by a Phase IIa Randomised, Open-label Trial Among Adolescents Comparing ChAdOx1 85A Prime Followed by MVA 85A Boost Versus BCG Re-vaccination. Recruiting NCT03681860 Phase 1, Phase 2
39 MVA-BN Imvamune Smallpox Vaccine Virus for Treatment of Basal Cell Carcinoma, Squamous Cell Carcinomas Recruiting NCT04410874 Phase 1, Phase 2
40 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study Terminated NCT00053508 Phase 2
41 MVA-BN (IMVAMUNE®) Immunization in Persons Who Have Undergone Prior Hematopoietic Stem Cell Transplant (HSCT): A Phase I, Placebo-Controlled Study of the Safety, Reactogenicity and Immunogenicity of MVA Immunization Completed NCT00565929 Phase 1 Placebo
42 The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination Completed NCT00079820 Phase 1
43 A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults Completed NCT02743455 Phase 1 ISA-720
44 An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders Completed NCT00189917 Phase 1
45 Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years Completed NCT00189969 Phase 1
46 Evaluation of Human Immune Response to Smallpox Vaccine (Vaccinia Virus) Completed NCT00068198 Phase 1
47 A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®) Completed NCT00042094 Phase 1
48 A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers Completed NCT00002261 Phase 1
49 Randomized, Double Blind, Placebo Control Study to Evaluate the Safety and Immunogenicity of CJ-50300 in Healthy Volunteers : Phase I Completed NCT00336635 Phase 1
50 Phase I Study on Safety, Tolerability and Immunogenicity of the MVA-BN Vaccine Administered to Healthy Subjects Completed NCT00189943 Phase 1

Search NIH Clinical Center for Variola Major

Genetic Tests for Variola Major

Anatomical Context for Variola Major

The Foundational Model of Anatomy Ontology organs/tissues related to Variola Major:

19
Skin

MalaCards organs/tissues related to Variola Major:

40
Skin, T Cells, Eye, Bone Marrow, Kidney, Brain, Breast

Publications for Variola Major

Articles related to Variola Major:

(show top 50) (show all 7129)
# Title Authors PMID Year
1
Offline: The lessons of smallpox eradication for COVID-19. 61
33341128 2021
2
Reemergence of Human Monkeypox and Declining Population Immunity in the Context of Urbanization, Nigeria, 2017-2020. 61
33756100 2021
3
Smallpox in art: considerations on some of its medical and social aspects. 61
33811419 2021
4
Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice. 61
33801026 2021
5
Clinical and epidemiologic findings from enhanced monkeypox surveillance in Tshuapa Province, Democratic Republic of the Congo during 2011-2015. 61
33728469 2021
6
The history of the antibody as a tool. 61
33721607 2021
7
Modelling of optimal vaccination strategies in response to a bioterrorism associated smallpox outbreak. 61
33734944 2021
8
Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103. 61
33685392 2021
9
Smallpox vaccination in the 19th century. 61
33749842 2021
10
[Salting a Newborn Baby as a Prophylactic Against Smallpox]. 61
33749186 2021
11
An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. 61
32882158 2021
12
Smallpox scars in a 19th-century portrait at the Turku Art Museum. 61
33025613 2021
13
Friedelin exhibits antidiabetic effect in diabetic rats via modulation of glucose metabolism in liver and muscle. 61
33271243 2021
14
The history of light therapy in hospital physiotherapy and medicine with emphasis on Australia: Evolution into novel areas of practice. 61
33678141 2021
15
Myopericarditis Associated With Smallpox Vaccination Among US Army Personnel - Fort Hood, Texas, 2018. 61
33719991 2021
16
Rethinking disease eradication: putting countries first. 61
33693720 2021
17
One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. 61
33688035 2021
18
[Development and use of vaccines from the 18th century to the SARS-CoV 2 period]. 61
33734072 2021
19
Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2? 61
33800626 2021
20
There are no in-principle ethical objections to controlled voluntary SARS-CoV-2 infection. 61
33393089 2021
21
Direct Priming of CD8+ T Cells Persists in the Face of Cowpox Virus Inhibitors of Antigen Presentation. 61
33692206 2021
22
Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated and antibody dependent cellular cytotoxicity responses. 61
33675226 2021
23
Targeting tumour necrosis factor to ameliorate viral pneumonia. 61
33624419 2021
24
(+)-Camphor and (-)-borneol derivatives as potential anti-orthopoxvirus agents. 61
33605479 2021
25
Vaccinia virus-based vector against infectious diseases and tumors. 61
33606578 2021
26
COVID-19, varying genetic resistance to viral disease and immune tolerance checkpoints. 61
33113212 2021
27
A critical assessment of proposed outbreaks of plague and other epidemic diseases in Ancient Egypt. 61
33227516 2021
28
Protection against severe infectious disease in the past. 61
33573529 2021
29
Correction for Hutson et al., "Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model". 61
33597175 2021
30
Live Vaccinia Virus-Coated Microneedle Array Patches for Smallpox Vaccination and Stockpiling. 61
33546332 2021
31
Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. 61
33536322 2021
32
Biosecurity risks associated with vaccine platform technologies. 61
33640142 2021
33
A class of viral inducer of degradation of the necroptosis adaptor RIPK3 regulates virus-induced inflammation. 61
33444549 2021
34
Maternal vaccines-safety in pregnancy. 61
33773923 2021
35
"An epoch-making and blessed moment in the history of medicine" -thoughts on international health equity and the Nobel prize in medicine. 61
33568125 2021
36
[THE VACCINATION CONTROVERSY IN THE JEWISH COMMUNITY IN LONDON IN THE LATE 19TH CENTURY: "NOTHING IS NEW UNDER THE SUN"]. 61
33474878 2021
37
Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. 61
33422381 2021
38
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease. 61
33442693 2021
39
A novel and sensitive real-time PCR system for universal detection of poxviruses. 61
33469067 2021
40
Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge. 61
33398010 2021
41
James Phipps, first to be vaccinated against smallpox by Edward Jenner. 61
33251953 2021
42
Triumphs and tribulations of COVID-19 vaccines: Lessons to be learned from smallpox epidemics in the 1700s. 61
33432481 2021
43
Neurologic Manifestations of the World Health Organization's List of Pandemic and Epidemic Diseases. 61
33692745 2021
44
Human ABO Blood Groups and Their Associations with Different Diseases. 61
33564677 2021
45
Interleukin 35 Regulatory B Cells. 61
32755620 2021
46
Smallpox Eradication: African Origin, African Solutions, and Relevance for COVID-19. 61
33534731 2021
47
Future perspectives on swine viral vaccines: where are we headed? 61
33397477 2021
48
Superspreaders: A Lurking Danger in the Community. 61
33448254 2021
49
Future threat from the past. 61
33068243 2021
50
Arnold Theiler and colleagues: a -successful cooperation between -Switzerland and South Africa. 61
33528367 2021

Variations for Variola Major

Expression for Variola Major

Search GEO for disease gene expression data for Variola Major.

Pathways for Variola Major

Pathways related to Variola Major according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.67 DUSP7 DUSP3 DUSP1
2 10.54 CD8A CD4

GO Terms for Variola Major

Biological processes related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine dephosphorylation GO:0035335 9.73 DUSP1 DUSP14 DUSP22 DUSP29 DUSP3 DUSP7
2 inactivation of MAPK activity GO:0000188 9.55 DUSP1 DUSP14 DUSP29 DUSP3 DUSP7
3 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.5 DUSP1 DUSP29 DUSP3
4 protein dephosphorylation GO:0006470 9.5 DUSP1 DUSP14 DUSP22 DUSP29 DUSP3 DUSP7
5 negative regulation of MAPK cascade GO:0043409 9.4 DUSP1 DUSP3
6 peptidyl-threonine dephosphorylation GO:0035970 9.37 DUSP1 DUSP7
7 dephosphorylation GO:0016311 9.17 DUSP1 DUSP14 DUSP22 DUSP29 DUSP3 DUSP7

Molecular functions related to Variola Major according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.95 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14 DUSP1
2 phosphoprotein phosphatase activity GO:0004721 9.8 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14 DUSP1
3 protein tyrosine phosphatase activity GO:0004725 9.73 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14 DUSP1
4 protein serine/threonine phosphatase activity GO:0004722 9.63 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14 DUSP1
5 protein tyrosine kinase binding GO:1990782 9.58 DUSP3 DUSP22 CD4
6 MAP kinase tyrosine/serine/threonine phosphatase activity GO:0017017 9.54 DUSP7 DUSP14 DUSP1
7 phosphatase activity GO:0016791 9.5 STYXL2 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14
8 mitogen-activated protein kinase binding GO:0051019 9.49 DUSP7 DUSP1
9 protein tyrosine/threonine phosphatase activity GO:0008330 9.46 DUSP7 DUSP1
10 MAP kinase phosphatase activity GO:0033549 9.43 DUSP3 DUSP29
11 protein tyrosine/serine/threonine phosphatase activity GO:0008138 9.17 STYXL2 DUSP7 DUSP3 DUSP29 DUSP22 DUSP14

Sources for Variola Major

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....